ValuEngine downgraded shares of Albireo Pharma (NASDAQ:ALBO) from a strong-buy rating to a buy rating in a research report report published on Wednesday, ValuEngine reports.

ALBO has been the topic of a number of other reports. BidaskClub downgraded shares of Albireo Pharma from a sell rating to a strong sell rating in a research report on Tuesday, October 1st. Zacks Investment Research raised shares of Albireo Pharma from a sell rating to a hold rating in a research report on Monday, November 11th. HC Wainwright reaffirmed a buy rating and set a $62.00 price objective on shares of Albireo Pharma in a research report on Sunday, August 11th. Cowen reaffirmed a buy rating and set a $39.00 price objective on shares of Albireo Pharma in a research report on Wednesday, November 6th. Finally, Wedbush reaffirmed a buy rating and set a $69.00 price objective on shares of Albireo Pharma in a research report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of $48.75.

Albireo Pharma stock opened at $18.24 on Wednesday. The firm has a 50-day moving average price of $18.64 and a two-hundred day moving average price of $26.65. The firm has a market capitalization of $233.69 million, a price-to-earnings ratio of -4.63 and a beta of 1.47. Albireo Pharma has a 52-week low of $16.13 and a 52-week high of $38.69.

Albireo Pharma (NASDAQ:ALBO) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($1.73) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.55) by ($0.18). Albireo Pharma had a negative net margin of 1,881.86% and a negative return on equity of 62.69%. The company had revenue of $1.39 million for the quarter, compared to analysts’ expectations of $1.38 million. Research analysts anticipate that Albireo Pharma will post -6.07 earnings per share for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Man Group plc grew its position in Albireo Pharma by 770.4% in the second quarter. Man Group plc now owns 189,500 shares of the biopharmaceutical company’s stock worth $6,109,000 after acquiring an additional 167,729 shares in the last quarter. BlackRock Inc. grew its position in Albireo Pharma by 14.7% in the second quarter. BlackRock Inc. now owns 658,767 shares of the biopharmaceutical company’s stock worth $21,239,000 after acquiring an additional 84,575 shares in the last quarter. Chicago Capital LLC grew its position in Albireo Pharma by 10.0% in the third quarter. Chicago Capital LLC now owns 222,549 shares of the biopharmaceutical company’s stock worth $4,451,000 after acquiring an additional 20,308 shares in the last quarter. Vanguard Group Inc. grew its position in Albireo Pharma by 10.1% in the second quarter. Vanguard Group Inc. now owns 177,647 shares of the biopharmaceutical company’s stock worth $5,727,000 after acquiring an additional 16,236 shares in the last quarter. Finally, Marshall Wace North America L.P. grew its position in Albireo Pharma by 57.4% in the second quarter. Marshall Wace North America L.P. now owns 39,888 shares of the biopharmaceutical company’s stock worth $1,286,000 after acquiring an additional 14,544 shares in the last quarter. 73.21% of the stock is currently owned by hedge funds and other institutional investors.

About Albireo Pharma

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

See Also: Cash Asset Ratio

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.